Middle East and Africa Nasal Spray Market _Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Middle East and Africa Nasal Spray Market _Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025


  • Products Id :- DBMR750
  • |
  • Pages: 100
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Market Definition

Nasal sprays are the devices that help in the delivery of the drug through the nose in the nasal cavity to treat allergy and other problems related to brain inflammation, diabetes, dental problems, central nervous system. Allergy is a condition in which immune system of the body reacts abnormally to a foreign substance. Nasal spray drug products consist of therapeutically active ingredients or drug substances in the form of solution or suspension of excipients. There are different types of nasal spray available in market such as decongestion nasal spray, saline nasal spray and steroid nasal spray. Decongestants are used to treat nasal congestion which provides short-term relief for a blocked or stuffy nose. Decongestion nasal spray comprises of drugs which shrinks the swollen membranes and open ups the airways of the nasal part which makes the breathing process easier.

Middle East & Africa nasal spray market is expected with healthy CAGR of 5.0% in the forecast period of 2018 to 2025. The new market report contains data for the historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Market Segmentation:

By Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/ Saline Nasal Spray, Others), Container Design (Pressurized Canisters, Pump Bottles), Dosage Form (Unit/Single Dose, Bi Dose, Multi Dose), Prescription Mode (Over the Counter, Prescription Based), Therapeutic Class (Antihistamine, Nasal Steroids, Mast Cell Inhibitor, Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, Others), End User (Home Care Settings, Hospitals, Clinics, Community Health Care), Country (South Africa, Egypt, Saudi Arabia, United Arab Emirates, Israel, Rest of Middle East and Africa)

Major growing sectors under the market segmentation are as follows:

In product type, decongestion nasal spray segment is expected to dominate the global nasal spray market due to the rising problems associated with the decongestion of conditions such as colds & flu, hay fever, allergic reactions and sinusitis are helping the segment to grow in the forecast period of 2018 to 2025.

In therapeutic class, antihistamine segment is expected to dominate the market due to rising antihistamine usage amongst population for different diseases such as congestion, runny nose, sneezing, itching, nasal swelling and different products availability by the companies is expected to dominate the market, whereas nasal steroids are available for both prescription and over the counter usage, and fast effective results are the major growth factors of the market.

In container design, pump bottles segment is expected to dominate the market due to the user friendly and wide offering of the over the counter products by the companies and it is expected to fuel the growth of pump bottles market in the forecast period. However, new advancement associated with the pressurized canisters.

In doses form, multi does segment is expected to dominate the market due to the wide availability in different dose volumes and user friendly attributes it is expected to drive the market of unit/single dose in the forecast period.

In prescription segment, prescription based segment is expected to dominate the market due to the rising chances of seasonal associated nasal problems and also for the various diseases such as pulmonary, dental anesthesia and others which leads the growth of prescription based segment is expected to fuel in the forecast period of 2018 to 2025.

In application segment, nasal congestion segment is expected to dominate the market due to the rising cases of nasal congestion diseases such as runny nose, sinus pain, mucus buildup and also availability of the over the counter products, nasal congestion segment is expected to dominate market. However, allergic and non-allergic rhinitis is the fastest growing segment among all because of the rising problems amongst the population such as antihistamines, nasal corticosteroids, hay fever and other, also seasonal imbalance is one of the reasons in raising the allergic and non-allergic rhinitis segment to grow in the forecast period with the highest CAGR.

The key market players for Middle East & Africa nasal spray market are listed below:

ADAPT Pharma, Inc.

Sandoz International GmbH

INNOVUS PHARMACEUTICALS, INC.

Cipla Inc.

Aurena

J Pharmaceuticals

Bayer AG

St. Renatus

ARIUS FORMULATIONS PVT LTD

Ultratech India Limited

GlaxoSmithKline plc

Egalet Corporation

LEEFORD HEALTHCARE LTD

Aishwarya Group



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

TABLE OF CONTENTS

1 INTRODUCTION 20

1.1 OBJECTIVES OF THE STUDY 20

1.2 MARKET DEFINITION 20

1.3 OVERVIEW OF NASAL SPRAY MARKET 21

1.4 CURRENCY AND PRICING 22

1.5 LIMITATION 22

1.6 MARKETS COVERED 22

2 MARKET SEGMENTATION 25

2.1 MARKETS COVERED 25

2.2 GEOGRAPHIC SCOPE 26

2.3 YEARS CONSIDERED FOR THE STUDY 27

2.4 CURRENCY AND PRICING 27

2.5 RESEARCH METHODOLOGY 28

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31

2.7 SECONDARY SOURCES 32

2.8 ASSUMPTIONS 32

3 MARKET OVERVIEW 33

3.1 DRIVERS 35

3.1.1 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 35

3.1.2 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 36

3.1.3 INCREASE IN INFECTION & ALLERGIC CASES 37

3.2 RESTRAINTS 37

3.2.1 PRODUCT RECALLS 37

3.3 OPPORTUNITIES 38

3.3.1 NEW RISING DEMAND FOR SELF ADMINISTRATIVE DRUG DELIVERY 38

3.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 38

3.4 CHALLENGES 39

3.4.1 REGULATORY HURDLES 39

4 EXECUTIVE SUMMARY 40

5 PREMIUM INSIGHTS 43

?

6 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE 45

6.1 OVERVIEW 46

6.2 DECONGESTION NASAL SPRAY 48

6.3 SALT WATER SOLUTION/ SALINE NASAL SPRAY 49

6.4 STEROID NASAL SPRAY 51

6.5 OTHERS 52

7 MIDDLE EAST AND AFRICA N ASAL SPRAY MARKET, BY CONTAINER DESIGN 53

7.1 OVERVIEW 54

7.2 PRESSURIZED CANISTERS 56

7.3 PUMP BOTTLES 57

8 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM 58

8.1 OVERVIEW 59

8.2 UNIT/SINGLE DOSE 61

8.3 BI DOSE 63

8.4 MULTI DOSE 64

9 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 66

9.1 OVERVIEW 67

9.2 ANTIHISTAMINE 69

9.3 NASAL STEROIDS 71

9.4 MAST CELL INHIBITOR 72

9.5 ANTICHOLINERGIC 73

10 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY APPLICATION 74

10.1 OVERVIEW 75

10.2 ALLERGIC AND NON-ALLERGIC RHINITIS 77

10.3 NASAL CONGESTION 79

10.4 CENTRAL NERVOUS SYSTEM DISORDERS 80

10.5 VACCINATION 81

10.6 OTHERS 82

11 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION MODE 83

11.1 OVERVIEW 84

11.2 PRESCRIPTION BASED 86

11.3 OVER THE COUNTER 87

?

12 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY END USER 89

12.1 OVERVIEW 90

12.2 HOSPITALS 92

12.3 CLINICS 93

12.4 HOME CARE SETTINGS 94

12.5 COMMUNITY HEALTH CARE 95

13 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY GEOGRAPHY 96

13.1 MIDDLE EAST AND AFRICA 96

13.1.1 GROWING PREFERENCES FOR DRUG ADMINISTRATION THROUGH INTRA NASAL ROUTE 96

13.1.2 SOUTH AFRICA 104

13.1.3 EGYPT 105

13.1.4 SAUDI ARABIA 106

13.1.5 UNITED ARAB EMIRATES 107

13.1.6 ISRAEL 107

13.1.7 REST OF MIDDLE EAST & AFRICA 108

14 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, COMPANY LANDSCAPE 109

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 109

15 COMPANY PROFILE 110

15.1 PFIZER INC. 110

15.1.1 COMPANY OVERVIEW 110

15.1.2 REVENUE ANALYSIS 110

15.1.3 COMPANY SHARE ANALYSIS 111

15.1.4 PRODUCT PORTFOLIO 112

15.1.5 RECENT DEVELOPMENTS 112

15.2 CIPLA INC. 113

15.2.1 COMPANY OVERVIEW 113

15.2.2 REVENUE ANALYSIS 113

15.2.3 COMPANY SHARE ANALYSIS 114

15.2.4 PRODUCT PORTFOLIO 114

15.2.5 RECENT DEVELOPMENTS 115

15.3 BAYER AG 116

15.3.1 COMPANY OVERVIEW 116

15.3.2 REVENUE ANALYSIS 116

15.3.3 COMPANY SHARE ANALYSIS 117

15.3.4 PRODUCT PORTFOLIO 117

15.3.5 RECENT DEVELOPMENTS 117

15.4 INNOVUS PHARMACEUTICALS, INC. 118

15.4.1 COMPANY OVERVIEW 118

15.4.2 REVENUE ANALYSIS 118

15.4.3 COMPANY SHARE ANALYSIS 119

15.4.4 PRODUCT PORTFOLIO 119

15.4.5 RECENT DEVELOPMENTS 119

15.5 GLAXOSMITHKLINE PLC. 120

15.5.1 COMPANY OVERVIEW 120

15.5.2 REVENUE ANALYSIS 120

15.5.3 PRODUCT PORTFOLIO 121

15.5.4 RECENT DEVELOPMENTS 121

15.6 ADAPT PHARMA, INC. 122

15.6.1 COMPANY OVERVIEW 122

15.6.2 GEOGRAPHIC PRESENCE 122

15.6.3 PRODUCT PORTFOLIO 123

15.6.4 RECENT DEVELOPMENTS 123

15.7 AISHWARYA GROUP 124

15.7.1 COMPANY OVERVIEW 124

15.7.2 PRODUCT PORTFOLIO 124

15.7.3 RECENT DEVELOPMENTS 124

15.8 ALLERGAN 125

15.8.1 COMPANY OVERVIEW 125

15.8.2 REVENUE ANALYSIS 125

15.8.3 PRODUCT PORTFOLIO 125

15.8.4 RECENT DEVELOPMENTS 126

15.9 ARIUS FORMULATIONS PVT LTD 127

15.9.1 COMPANY OVERVIEW 127

15.9.2 PRODUCT PORTFOLIO 127

15.9.3 RECENT DEVELOPMENTS 127

15.10 AURENA 128

15.10.1 COMPANY OVERVIEW 128

15.10.2 GEOGRAPHIC PRESENCE 128

15.10.3 PRODUCT PORTFOLIO 129

15.10.4 RECENT DEVELOPMENTS 129

15.11 CATALENT, INC 130

15.11.1 COMPANY OVERVIEW 130

15.11.2 REVENUE ANALYSIS 130

15.11.3 PRODUCT PORTFOLIO 131

15.11.4 RECENT DEVELOPMENTS 131

15.12 EGALET CORPORATION 132

15.12.1 COMPANY OVERVIEW 132

15.12.2 REVENUE ANALYSIS 132

15.12.3 PRODUCT PORTFOLIO 133

15.12.4 RECENT DEVELOPMENTS 133

15.13 J PHARMACEUTICALS 134

15.13.1 COMPANY OVERVIEW 134

15.13.2 PRODUCT PORTFOLIO 134

15.13.3 RECENT DEVELOPMENTS 134

15.14 LEEFORD HEALTHCARE LTD 135

15.14.1 COMPANY OVERVIEW 135

15.14.2 GEOGRAPHIC PRESENCE 135

15.14.3 PRODUCT PORTFOLIO 136

15.14.4 RECENT DEVELOPMENTS 136

15.15 MYLAN N.V. 137

15.15.1 REVENUE ANALYSIS 137

15.15.2 PRODUCT PORTFOLIO 138

15.15.3 RECENT DEVELOPMENTS 138

15.16 SANDOZ INTERNATIONAL GMBH 139

15.16.1 COMPANY OVERVIEW 139

15.16.2 GEOGRAPHIC PRESENCE 139

15.16.3 PRODUCT PORTFOLIO 140

15.16.4 RECENT DEVELOPMENTS 140

15.17 ST. RENATUS 141

15.17.1 COMPANY OVERVIEW 141

15.17.2 PRODUCT PORTFOLIO 141

15.17.3 RECENT DEVELOPMENTS 141

15.18 TEVA PHARMACEUTICAL INDUSTRIES LTD. 142

15.18.1 COMPANY OVERVIEW 142

15.18.2 REVENUE ANALYSIS 142

15.18.3 PRODUCT PORTFOLIO 143

15.18.4 RECENT DEVELOPMENTS 143

15.19 ULTRATECH INDIA LIMITED 144

15.19.1 COMPANY OVERVIEW 144

15.19.2 PRODUCT PORTFOLIO 144

15.19.3 RECENT DEVELOPMENTS 144

16 RELATED REPORTS 145

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: SEGMENTATION 17

FIGURE 2 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: DATA TRIANGULATION 20

FIGURE 3 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: RESEARCH SNAPSHOT 21

FIGURE 4 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET:BOTTOM UP APPROACH 22

FIGURE 5 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET:TOP DOWN APPROACH 22

FIGURE 6 MIDDLE EAST AND AFRICANASAL SPRAY MARKET: INTERVIEW DEMOGRAPHICS 23

FIGURE 7 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA NASAL SPRAY MARKET 26

FIGURE 8 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: SEGMENTATION 34

FIGURE 9 IMPROVING PATIENT COMPLIANCE AND ACCEPTIBILITY AND EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY ARE EXPECTED TO DRIVE THE MARKET FOR NASAL SPRAY IN THE FORECAST PERIOD 2018 TO 2025 35

FIGURE 10 DECONGESTION NASAL SPRAY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NASAL SPRAY MARKET IN 2018 & 2025 36

FIGURE 11 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: BY PRODUCT TYPE, 2017 38

FIGURE 12 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2017 46

FIGURE 13 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: BY DOSAGE FORM, 2017 51

FIGURE 14 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2017 59

FIGURE 15 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: BY APPLICATION, 2017 67

FIGURE 16 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: BY PRESCRIPTION MODE, 2017 76

FIGURE 17 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: BY END USER, 2017 82

FIGURE 18 MIDDLE EAST & AFRICA NASAL SPRAY MARKET SNAPSHOT (2017) 89

FIGURE 19 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY COUNTRY (2017) 90

FIGURE 20 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY COUNTRY (2018 & 2025) 90

FIGURE 21 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY COUNTRY (2017 & 2025) 91

FIGURE 22 MIDDLE EAST & AFRICA NASAL SPRAY MARKET: BY PRODUCT TYPE (2018-2025) 91

FIGURE 23 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET: COMPANY SHARE 2017 (%) 101

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2016 -2025, (USD MILLION) 40

TABLE 2 MIDDLE EAST AND AFRICA DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 41

TABLE 3 MIDDLE EAST AND AFRICA SALT WATER SOLUTION/ SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 43

TABLE 4 MIDDLE EAST AND AFRICA STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, USD MILLION (2016 -2025) 44

TABLE 5 MIDDLE EAST AND AFRICA OTHERS IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 45

TABLE 6 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2016 -2025, (USD MILLION) 48

TABLE 7 MIDDLE EAST AND AFRICA PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 49

TABLE 8 MIDDLE EAST AND AFRICA PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 50

TABLE 9 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM, 2016 -2025, (USD MILLION) 53

TABLE 10 MIDDLE EAST AND AFRICA UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 55

TABLE 11 MIDDLE EAST AND AFRICA BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 56

TABLE 12 MIDDLE EAST AND AFRICA MULTI-DOSE IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 58

TABLE 13 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2016 -2025, (USD MILLION) 61

TABLE 14 MIDDLE EAST AND AFRICA ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 63

TABLE 15 MIDDLE EAST AND AFRICA NASAL STEROID IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 64

TABLE 16 MIDDLE EAST AND AFRICA MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 65

TABLE 17 MIDDLE EAST AND AFRICA ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 66

TABLE 18 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY APPLICATION, 2016 -2025, (USD MILLION) 69

TABLE 19 MIDDLE EAST AND AFRICA ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 71

TABLE 20 MIDDLE EAST AND AFRICA NASAL CONGESTION RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 72

TABLE 21 MIDDLE EAST AND AFRICA CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 73

TABLE 22 MIDDLE EAST AND AFRICA VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 74

TABLE 23 MIDDLE EAST AND AFRICA OTHERS IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 75

TABLE 24 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION MODE, 2016 -2025, (USD MILLION) 78

TABLE 25 MIDDLE EAST AND AFRICA PRESCRIPTION BASED IN NASAL SPRAY MARKET, BY REGION, USD MILLION (2016 -2025) 79

TABLE 26 MIDDLE EAST AND AFRICA OVER THE COUNTER BASED IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 81

TABLE 27 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY END USER, 2016 -2025, (USD MILLION) 84

TABLE 28 MIDDLE EAST AND AFRICA HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 85

TABLE 29 MIDDLE EAST AND AFRICA CLINICS IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 86

TABLE 30 MIDDLE EAST AND AFRICA HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 87

TABLE 31 MIDDLE EAST AND AFRICA COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2016 -2025, (USD MILLION) 88

TABLE 32 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY COUNTRY, 2016-2025, (USD MILLION) 93

TABLE 33 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2016-2025, (USD MILLION) 93

TABLE 34 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2016-2025, (USD MILLION) 94

TABLE 35 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM, 2016-2025, (USD MILLION) 94

TABLE 36 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2016-2025, (USD MILLION) 95

TABLE 37 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY APPLICATION, 2016-2025, (USD MILLION) 95

TABLE 38 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION MODE, 2016-2025, (USD MILLION) 96

TABLE 39 MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY END USER, 2016-2025, (USD MILLION) 96

TABLE 40 SOUTH AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2016-2025, (USD MILLION) 97

TABLE 41 SOUTH AFRICA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2016-2025, (USD MILLION) 97

TABLE 42 SOUTH AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM, 2016-2025, (USD MILLION) 98

TABLE 43 SOUTH AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2016-2025, (USD MILLION) 98

TABLE 44 SOUTH AFRICA NASAL SPRAY MARKET, BY APPLICATION, 2016-2025, (USD MILLION) 99

TABLE 45 SOUTH AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION MODE, 2016-2025, (USD MILLION) 99

TABLE 46 SOUTH AFRICA NASAL SPRAY MARKET, BY END USER, 2016-2025, (USD MILLION) 100

TABLE 47 REST OF MIDDLE EAST & AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2016-2025, (USD MILLION) 101

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

ADAPT Pharma, Inc.

Sandoz International GmbH

INNOVUS PHARMACEUTICALS, INC.

Cipla Inc.

Aurena

J Pharmaceuticals

Bayer AG

St. Renatus

ARIUS FORMULATIONS PVT LTD

Ultratech India Limited

GlaxoSmithKline plc

Egalet Corporation

LEEFORD HEALTHCARE LTD

Aishwarya Group

select a license
Single User License
USD 2500 INR 178900
Corporate User License
USD 3200 INR 228992

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com